Create your FREE profile now!
Join the discussion with physicians and researchers around the globe - sign up for your free Cureus account today.
Dr. Regine leads a department which has achieved a Top 5 national ranking in National Institutes of Health research funding. He is recognized nationally and internationally in the areas of gastrointestinal and central nervous system malignancies and in the use of stereotactic radiosurgery (SRS). As Executive Director of the Maryland Proton Treatment Center, he leads the first and most advanced facility of its kind in the Batlimore-Washington, DC region -- providing nearly 2,000 cancer patients a year with precise, "pencil-beam" technology to treat solid tumors.
Dr. Regine has served as principal or co-principal Investigator in at least four National Cancer Institute (NCI)-sponsored cooperative group clinical trials. He is a member of the GI and Brain Tumor steering committees for the NCI sponsored national cooperative clinical trials group known as NRG Oncology, and is the recent chairman of the GI section of the National Oral Board examination for trainees in radiation oncology. Dr. Regine served as the principal investigator of a study evaluating adjuvant therapy in patients with pancreatic cancer, which defined a new standard of care. He also has been the principal investigator/study chairman for two institutional clinical trials that defined new standards of care for patients with brain metastases and malignant spinal cord compression. Dr. Regine is co-editor of Principles and Practices of Stereotactic Radiosurgery, the first comprehensive textbook of its kind. He is also co-inventor of the first of its kind treatment device completely dedicated to the stereotactic radiation treatment of early stage breast cancer, known as the GammaPod.
Recent article categories: Medical Physics, Radiation Oncology, OncologyShow: